The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Over the last 50 years, evidence for central involvement of glutamatergic neurotransmission in the pathophysiology of schizophrenia has accumulated. Recent advances in neuroimaging technology now allow several components of glutamatergic neurotransmission to be assessed in the living human brain. Positron emission tomography (PET) or single photon emission tomography (SPET) in combination with select radiotracers allows visualization of glutamatergic receptors in vivo, and magnetic resonance (MR) - based techniques allow mapping of the effects of glutamatergic agents on regional brain activation, and the measurement of regional glutamate concentrations. These imaging studies have provided evidence for regional glutamatergic abnormalities in psychosis, and are beginning to describe both the evolution of these abnormalities over the course of the illness and their response to therapeutic intervention. In parallel, advances in small animal imaging and the development of animal models have provided a platform to explore the neuropathological consequences of glutamatergic abnormality, and the potential antipsychotic efficacy of novel compounds. The molecular diversity of the glutamatergic system has driven the design of several compounds targeting aspects of glutamatergic transmission, and clinical trials have yielded encouraging results. Here, we review the contribution of imaging studies to date in understanding glutamatergic abnormalities in psychosis, and discuss the potential of new glutamatergic compounds for treatment of the disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020 · cited 2×
“[12] Harrison, P.”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 2×
“[103] Moghaddam, B.”
BackgroundGlutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 5×
“Complementary to dopaminergic theories is the hypothesis that schizophrenia may arise due to abnormalities in glutamatergic neurotransmission [1-5].”
BackgroundMethodInfluentialAnis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 2×
“Electrophysiological recording studies in animals show that NMDAR antagonism increases the activity of prefrontal cortical neurons [99], and that this effect results from preferential inhibition of GABAergic interneurons by NMDAR antagonists, leading to disinhibition of pyramidal neuron activity [100].”
BackgroundPatil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040 · cited 2×
“[203] Patil, S.”
BackgroundNMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020 · cited 4×
“The observation that PCP and ketamine block NMDAR ion channels [25] led to the development of the hypothesis that schizophrenia may be a disorder of NMDAR hypofunction [4,5].”
BackgroundMethodInfluentialStudy of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917 · cited 3×
“[173] Coyle, J.”
BackgroundSchell, M. J., Molliver, M. E., & Snyder, S. H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3948 · Cited by 832 · cited 2×
“Drugs that prolong AMPAR channel open time by positive allosteric modulation, termed AMPAkines, thereby increase NMDAR activation, and may also increase extracellular D-serine levels [192].”
BackgroundThe Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568 · cited 4×
“ADX47273 [S-(4fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piper idin-1-yl}methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric”
BackgroundInfluentialKrystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530 · cited 4×
“Central to the glutamatergic hypothesis of schizophrenia is the observation that administration of noncompetitive NMDAR antagonists, such as phencyclidine (PCP) and ketamine, can induce behavioral and neuropsychological effects in healthy volunteers which resemble schizophrenia, and can profoundly exacerbate psychotic…”
BackgroundMethodInfluentialNMDA-dependent modulation of CA1 local circuit inhibition
Grunze, H., Rainnie, D., Hasselmo, M., Barkai, E., Hearn, E., McCarley, R., & Greene, R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-06-02034.1996 · Cited by 467 · cited 2×
“[97] Grunze, H.”
BackgroundKapur, S., & Seeman, P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001093 · Cited by 459 · cited 2×
“exposure and schizophrenia [19,28,35], and PCP and ketamine also have effects at other, non-NMDA, receptors [37].”
BackgroundHashimoto, T., Bazmi, H. H., Mirnics, K., Wu, Q., Sampson, A. R., & Lewis, D. A. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07081223 · Cited by 457
Glutamate, Dopamine, and Schizophrenia: From Pathophysiology to Treatment
LARUELLE, M., KEGELES, L. S., & ABI‐DARGHAM, A. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.063 · Cited by 437
Jackson, M. E., Homayoun, H., & Moghaddam, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308455101 · Cited by 430
Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics
BEASLEY, C., & REYNOLDS, G. (1997) · Schizophrenia Research · doi:10.1016/s0920-9964(96)00122-3 · Cited by 426 · cited 2×
“[111] Beasley, C.”
ResultAnand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426 · cited 2×
“[107] Anand, A.”
BackgroundBuchanan, R. W., Javitt, D. C., Marder, S. R., Schooler, N. R., Gold, J. M., McMahon, R. P., Heresco-Levy, U., & Carpenter, W. T. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06081358 · Cited by 419 · cited 3×
“However, one large, multi-centre trial failed to find beneficial effects of glycine treatment, [171], although plasma glycine concentrations were significantly lower than in previous studies [172].”
BackgroundResultVollenweider, F. X., Leenders, K. L., Øye, I., Hell, D., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00042-9 · Cited by 413 · cited 3×
“In contrast to the increases in frontal CBF and glucose utilization which are observed on acute ketamine administration [38,39,41-43], early S/PET studies of long-term abusers of PCP indicate that frontal blood flow and glucose utilization are reduced [54,55].”
Cognitive Dysfunction in Schizophrenia: Convergence of γ-Aminobutyric Acid and Glutamate Alterations
Lewis, D. A., & Moghaddam, B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1372 · Cited by 404
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.805 · Cited by 392
Morgan, C. J. A., Muetzelfeldt, L., & Curran, H. V. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02761.x · Cited by 373
Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Antonini, A., Maguire, P., Missimer, J., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00039-9 · Cited by 353
Rothman, D. L., Behar, K. L., Hyder, F., & Shulman, R. G. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142131 · Cited by 337 · cited 3×
“[106] Rothman, D.”
BackgroundMolecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336 · cited 2×
“Regional changes in NMDAR subunit transcript or protein expression have also been consistently reported, as have changes in other glutamate receptor subtypes (see [81]).”
BackgroundDeakin, J. F. W., Lees, J., McKie, S., Hallak, J. E. C., Williams, S. R., & Dursun, S. M. (2008) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2007.37 · Cited by 311 · cited 3×
“[45] Deakin, J.”
BackgroundRowland, L. M., Bustillo, J. R., Mullins, P. G., Jung, R. E., Lenroot, R., Landgraf, E., Barrow, R., Yeo, R., Lauriello, J., & Brooks, W. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.394 · Cited by 304
Neurotransmitter interactions in schizophrenia–therapeutic implications
Carlsson, A., Waters, N., & Carlsson, M. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00117-1 · Cited by 298
First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients
Pilowsky, L. S., Bressan, R. A., Stone, J. M., Erlandsson, K., Mulligan, R. S., Krystal, J. H., & Ell, P. J. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001751 · Cited by 278 · cited 3×
“, (2006), the inverse correlation between negative symptoms and NMDA receptor binding in the hippocampus detected in patients on typical antipsychotics was absent in clozapine-treated patients [87].”
BackgroundSelf-citationKrystal, J. H., Abi-Saab, W., Perry, E., D’Souza, D. C., Liu, N., Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1982-8 · Cited by 272
Stone, J. M., Day, F., Tsagaraki, H., Valli, I., McLean, M. A., Lythgoe, D. J., O'Gorman, R. L., Barker, G. J., & McGuire, P. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.05.006 · Cited by 231
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
Heresco-Levy, U., Ermilov, M., Lichtenberg, P., Bar, G., & Javitt, D. C. (2004) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00707-8 · Cited by 222 · cited 2×
“adjunctive treatment to typical or newer atypical non-clozapine antipsychotics have reported significant improvements in symptoms, with particular efficacy in improving functioning in the cognitive and negative domains [161-167].”
BackgroundThe NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls
Abi-Saab, W., D'Souza, D., Moghaddam, B., & Krystal, J. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979354 · Cited by 208
Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia
Théberge, J., Williamson, K. E., Aoyama, N., Drost, D. J., Manchanda, R., Malla, A. K., Northcott, S., Menon, R. S., Neufeld, R. W. J., Rajakumar, N., et al. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.033670 · Cited by 185 · cited 5×
“Specifically, no effect of antipsychotic treatment was found on the increases in glutamate and glutamine in the anterior cingulate cortex of first episode patients for up to 30 months of treatment [120] or the increases in the glutamate / glutamine ratio in the anterior cingulate cortex for up to 12 months of treatmen…”
BackgroundResultInfluentialLópez-Gil, X., Babot, Z., Amargós-Bosch, M., Suñol, C., Artigas, F., & Adell, A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301356 · Cited by 183 · cited 2×
“Disinhibition of pyramidal neuron activity would be expected to result in increased glutamate release - and microdialysis studies consistently show that systemic administration of NMDAR antagonists increases glutamate release in frontal cortical regions [101-104].”
BackgroundCorlett, P. R., Honey, G. D., Aitken, M. R. F., Dickinson, A., Shanks, D. R., Absalom, A. R., Lee, M., Pomarol-Clotet, E., Murray, G. K., McKenna, P. J., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.611 · Cited by 182 · cited 3×
“response when volunteers view fearful faces [46] perform tasks of verbal working memory / executive function [47-49], episodic memory [50,51], attention [48] and learning [27].”
BackgroundMethod1H-MRS at 4 Tesla in minimally treated early schizophrenia
Bustillo, J. R., Rowland, L. M., Mullins, P., Jung, R., Chen, H., Qualls, C., Hammond, R., Brooks, W. M., & Lauriello, J. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.121 · Cited by 153 · cited 4×
“Due to glutamateglutamine cycling following glutamate release, these increases in the glutamine/glutamate ratio may reflect increased glutamate release [132].”
BackgroundInfluentialOhrmann, P., Siegmund, A., Suslow, T., Pedersen, A., Spitzberg, K., Kersting, A., Rothermundt, M., Arolt, V., Heindel, W., & Pfleiderer, B. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.07.002 · Cited by 116
Stone, J. M., Erlandsson, K., Arstad, E., Squassante, L., Teneggi, V., Bressan, R. A., Krystal, J. H., Ell, P. J., & Pilowsky, L. S. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1047-x · Cited by 103 · cited 2×
“[89] Stone, J.”
BackgroundSelf-citationMcLoughlin, G. A., Ma, D., Tsang, T. M., Jones, D. N. C., Cilia, J., Hill, M. D., Robbins, M. J., Benzel, I. M., Maycox, P. R., Holmes, E., et al. (2009) · Journal of Proteome Research · doi:10.1021/pr800892u · Cited by 63 · cited 2×
“In terms of antipsychotic administration alone, 21 days treatment with clozapine or olanzapine, but not risperidone or aripiprazole, significantly reduced frontal cortical glutamine and glutamate, whilst effects in the hippocampus and striatum were more limited [156].”
Background
Cited by
Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience
Kesby, J., Eyles, D., McGrath, J., & Scott, J. (2018) · Translational Psychiatry · doi:10.1038/s41398-017-0071-9 · Cited by 352
Lobellova, V., Entlerova, M., Svojanovska, B., Hatalova, H., Prokopova, I., Petrasek, T., Vales, K., Kubik, S., Fajnerova, I., & Stuchlik, A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.03.006 · Cited by 47
Huang, Z., Davis Iv, H. H., Yue, Q., Wiebking, C., Duncan, N. W., Zhang, J., Wagner, N.-F., Wolff, A., & Northoff, G. (2015) · Human Brain Mapping · doi:10.1002/hbm.22841 · Cited by 43
Krivoy, A., Hochman, E., Sendt, K.-V., Hollander, S., Vilner, Y., Selakovic, M., Weizman, A., & Taler, M. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.05.040 · Cited by 33
Metadata
- Authors
- Egerton, A., & M. Stone, J.
- Venue
- Current Pharmaceutical Biotechnology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-05-01
- Volume
- 13
- Issue
- 8
- Pages
- 1500-1512
- ISSN
- 1389-2010 (ISSN-L)
- OpenAlex
- W2039474546
- Cited by
- 49
- References
- 43
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.